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Cognitive behavioral therapy for insomnia (CBT-I) is a treatment with moderate to large effects. These
effects are believed to be sustained long-term, but no systematic meta-analyses of recent evidence exist.
In this present meta-analysis, we investigate long-term effects in 30 randomized controlled trials (RCTs)
comparing CBT-I to non-active control groups. The primary analyses (n ¼ 29 after excluding one study
which was an outlier) showed that CBT-I is effective at 3-, 6- and 12-mo compared to non-active con-
trols: Hedges g for Insomnia severity index: 0.64 (3 m), 0.40 (6 m) and 0.25 (12 m); sleep onset latency:
0.38 (3 m), 0.29 (6 m) and 0.40 (12 m); sleep efficiency: 0.51 (3 m), 0.32 (6 m) and 0.35 (12 m). We
demonstrate that although effects decline over time, CBT-I produces clinically significant effects that last
up to a year after therapy.
© 2019 Elsevier Ltd. All rights reserved.Introduction
Insomnia constitutes a serious and common mental health
problem with a prevalence of around 6% in the general population
(i.e., DSM-IV-TR diagnosis [1]). Furthermore, 30% of the general
population suffers from symptoms of insomnia without meeting
the criteria of a diagnosis [2]. Insomnia disorder is characterized by
a persistent difficulty initiating or maintaining sleep, for three
months or longer and for at least three nights a week, resulting in
impaired daytime functioning and significant distress [3]. The dis-
order is associatedwith high (societal) costs [4] and affects daily life
in various domains, such as fatigue, mood changes, declined
cognitive ability, physical wellbeing, social relationships and daily
tasks [5]. Untreated insomnia often persists for many years [6].chology, Faculty of Behavior
Boechorststraat 7, 1081 BT,
r Zweerde).Cognitive behavioral therapy (CBT) is an effective treatment for
insomnia. Several systematic reviews and meta-analyses have re-
ported moderate to large short-term post-test effects of CBT for
insomnia (CBT-I) [7e9]. These results include robust improvement
in insomnia severity (g ¼ 0.98; [9]) and sleep efficiency (g ¼ 0.71
[9]; g ¼ 0.91 [8]; and 9.9% increase in [7]).
In the short term, CBT-I is as effective as pharmacotherapy [10].
However, CBT-I is the preferred treatment according to recom-
mendations in European and American guidelines [11,12]. One
reason for advocating CBT-I as first line treatment for insomnia is
the risk sleep medication poses of patients developing serious side
effects (i.e., dizziness, drowsiness, addiction, and relapse when
medication is discontinued). Also, there is insufficient evidence for
long-term effects of pharmacotherapy, and therefore long-term use
of pharmacotherapy is not recommended [11e14]. Based on this
lack of evidence for pharmacotherapy's long-term benefits, CBT-I is
now regarded the better choice in the long-term [13]. In other
words, it is assumed that CBT-I has long-term effects. Several liter-
ature reviews indeed report CBT-I's effects may be durable
[10,15,16], but they lack a quantitative data synthesis of recent ev-
idence. To our knowledge, no meta-analysis has been published
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DSM diagnostic and statistical manual of mental disorders
DSISD Duke structured interview for sleep disorders
ICSD International classification of sleep disorders
ES effect size
F2F face-to-face
ISI insomnia severity index
MA meta-analysis




PSQI Pittsburgh sleep quality index





SIS-D structured interview for sleep disorders for DSM-III-R
SOL sleep onset latency
SR sleep restriction
SQ sleep quality
TST total sleep time
WASO wake after sleep onset
WL wait-list
T. van der Zweerde et al. / Sleep Medicine Reviews 48 (2019) 1012082that included controlled studies reporting on long-term effects of
(partial) CBT-I. Thus, it is unclear what the actual long-term effects
of CBT-I are.
In the present meta-analysis, we aim to fill this gap in the
literature by including all available RCTs reporting on the controlled
long-term effects of CBT-I (at three, six and 12 mo) and quantifying
these long-term effects of CBT-I. The focus of the present meta-
analysis is on subjective sleep outcomes, in terms of both self-
reported symptoms and sleep diaries.
Method
Protocol
Details of the protocol for this meta-analysis were registered on
PROSPERO and can be accessed at www.crd.york.ac.uk/PROSPERO/
display_record.asp?ID¼CRD42018094459.
Search strategy
Using our previous meta-analysis [9] as a starting point, we first
checked whether the included studies (n ¼ 87) had reported
controlled follow-up measurements in the original papers or had
published follow-up data since. This process included screening the
original papers for mention of follow-up measurements done or
planned, and literature search for publications from the different
research groups in the five years following the first publication,
using search terms “long”, “long()term” and “follow()up”.
Additionally, we performed searches in Web of Science, Pubmed
and PsycINFO for publications by the authors of the original article
on short-term effects to see if since then long-term effects had been
published.
We then performed a new search, covering the period from the
end of the search (December 2015) of the previous meta-analysis
[9] until May 2018. An extensive literature search was carried out
in PubMed, PsycINFO, EMBASE and the Cochrane central register of
controlled trials, using the same search strategy as in the previous
meta-analysis [9]. Terms indicative of insomnia (i.e., insomnia,
sleep disorders, sleep initiation and maintenance disorders) were
paired with terms indicating psychological treatments (i.e., psy-
chotherapy, cognitive therapy, behavior therapy). For example, our
PsycINFO database query was “(DE¼(“sleep disorders” or
“insomnia")) and(DE¼(“psychotherapy” or “behavior therapy” or“cognitive behavior therapy” or “cognitive therapy”))”, and speci-
fying we looked for results from December 2015 onwards.
Titles and abstracts were screened by two persons individually
(TvdZ and LB) and then crosschecked. Records definitely not
meeting criteria (e.g., not a randomized trial), not aimed at
insomnia, not psychological but a biological or medical treatment,
not an original research report (e.g., a meta-analysis) were excluded
based on title and/or abstract. We retrieved the full papers of the
remaining 70 references. Two researchers assessed the papers
independently (TvdZ and LB). When there was disagreement, the
paper was discussed (TvdZ, LB, JL, AvS) until consensus was
reached.
Inclusion and exclusion criteria
Inclusion criteria were: 1) randomized controlled trial (RCT); 2)
investigating CBT-I or at least one component of it (see below); 3) in
adults (18 y and older); 4) with self-reported and/or formally
diagnosed insomnia complaints (see Table 1); 5) compared to a
non-active control group (e.g., waitlist control, care-as-usual, or a
minimal intervention (e.g., education about sleep or sleep hygiene
information); 6) including data for sleep diary outcomes; 7)
reporting controlled follow-up data for 12 or more weeks after
post-test; 8) providing suitable data to calculate effect sizes.
The following components were identified as being part of CBT-
I: relaxation (RE), sleep restriction therapy (SRT), stimulus control
therapy (SC), paradoxical intention (PI), and identifying and chal-
lenging dysfunctional thoughts (about sleep), i.e., cognitive therapy
(CT). All monotherapy (only one CBT-I-component. e.g., RE or SRT
only) studies were included in line with the previous M-A [9], to
ensure not overestimating effects by only taking full (current) CBT-I
into account. All other therapies were excluded (e.g., interpersonal
therapy, bright light therapy, exercise, tai chi, biofeedback). Studies
on treatment in children or adolescents, on tapering medication
use or aimed at treating a different mental health disorder and
reporting on insomnia secondarily were also excluded.
Data extraction
We coded the following characteristics of the studies: 1) pub-
lication year, 2) recruitment setting (community, primary care,
other care facilities, university), 3) the insomnia definition used, 4)
comorbidity (e.g., insomnia in breast cancer patients), 5) age group
Table 1
Characteristics of the included studies on (elements of) CBT for insomnia.
Study Recruitment Definition
insomnia







Co-morbidity Age Intervention format F2F sess Control
group
Alessi 2016 [52] Comm
(veterans)
ICSD-2 criteria 6 m þ 12 m 159 FU1: Tx 92/106 (87%); C
52/53 (98%)







2 f2f, 2 phone Psychoeducation
Arnedt 2013 [45] Care wake
time > 60 m þ SE < 85%
3 m 33 Tx 15/15 (100%); C 12/15
(80%)
Excluded 18e65 CBT-I Phone 4e8 Info
Borkovec &
Weerts1976 [24]
Univ Average SOL  30 min 12 m 24 n/a (Tx: n ¼ 11; C: n ¼ 5) Allowed e Relaxation Group 4 No txt
Casault 2015 [51] Care ISI8 3 m þ 6 m 38 FU1 and FU2: Tx: 15/20




18e75 CBT-I Self-help þ
phone consult
n/a No txt
Creti 2005 [35] Comm No formal criteria. Poor




reported to have sleep
onset insomnia (>30 min
of undesired wakefulness
>2 times per week,
problem duration >6 mo;
10% of sample), sleep
maintenance insomnia
(duration of awakenings
after sleep onset >30, >2
times per week, problem
duration > 6 mo; 49% of
sample), or both (41% of
sample).”
12 m 27 51% of the sample Excluded 55þ Relaxation Self-help n/a No txt
Currie 2000 [30] Care DSM-III insomnia
diagnosis with SIS-D and
ICSD diagnosis
3m 60 Tx: 28/32 (88%); C 23/28
(82%)
Pain <60 CBT-I Group 7 WL
Edinger 2005 [36] Comm mean WASO 60 m 6 m 36 Tx: 6/18 (33%); C-SH: 7/
18 (39%); C-TAU 7/11
(64%)
Fibromyalgia 21e65 Behavioral Indiv 6 SH/TAU
Edinger 2009 [41] Care mean
SOL þ WASO  60 m




e Behavioral Indiv 4 Info
Espie 2001 [23] Care ICSD difficulty falling/
maintaining sleep,  4 n/
w,  3 mo þ PSQI  5
12 m 139 78% of the total sample Excluded e CBT-I Group 6 WL
Espie 2007 [39] Care ICSD/DSM-IV criteria of
insomnia
6 m 201 Tx: 76/107 (71%); C 67/94
(71%)
Allowed e CBT-I Group 5 No txt
Espie 2008 [40] Care SOL or WASO  30 m,  3
n/w,  3 mo þ PSQI  5
6 m 150 Tx: 67/100 (67%); C:39/50
(78%)
Cancer 18þ CBT-I Group 5 No txt
Friedman 2000 [31] Comm SE < 80%, SOL >30m,
TST < 6hr, WASO > 30 m,
 5 n/2w
3 m 39 Tx: 88%; C: 100% Excluded 55þ Behavioral Indiv 5 Info
Fuller 2016 [53] Pharmacy
care

























Table 1 (continued )
Study Recruitment Definition
insomnia







Co-morbidity Age Intervention format F2F sess Control
group
Irwin 2014 [46] Comm SOL or WASO  3 n/w, 
3 mo þ daytime imp
6 m þ 12 m 75 Tx: 46/50 (92%); C: 23/25
(92%)
Excluded 55þ PE þ SC þ
CT þ Relaxation
Group 16 Info
Jansson 2012 [42] Care SOL or WASO > 30 m,  3
n/w,  6 mo þ daytime
imp




18e65 CBT-I Indiv 7 WL
Jernelov 2012 [43] Comm ISI > 10 þ poor sleep  4
wk
3 m 133 Tx1: 41/44 (93%); Tx2:
39/45 (87%); C: 39/44
(89%)
Excluded 18þ CBT-I Self-help N/A WL
Jungquist 2010 [22] Care SOL or WASO > 30 m, > 3
n/w, > 6 mo
3 mþ6 m 28 Both FU's: Tx: 15/19
(79%); C: 5/9 (56%)
Pain 25þ CBT-I Indiv 8 Plac
Kaldo 2015 [49] Comm Difficulty initiating or
maintaining
sleep þ daytime
imp þ ISI > 10
6 m þ 12 m 148 Tx: 54/73 (74%); C: 53/75
(71%)
Excluded 18þ CBT-I Self-help n/a Plac
Lacks 1983 [29] Comm WASO 30 m, 1 n/w,
6 mo
3 m 64 Tx: 7/15 (47%); C 8/16
(50%)
Excluded 17e59 SC Group 4 Plac
Lichtstein 2000 [32] Comm SOL or WASO  30 m,  3
n/w,  6 mo þ daytime
imp
3 m 44 Tx: 22/23 (96%); C: 17/21
(81%)
Illness 58þ Relaxation þ
SC
Indiv 4 WL
Lichtstein 2001 [33] Comm SOL or WASO  30 m,  3
n/w,  6 mo þ daytime
imp
12 m 89 83% of the total sample Excluded 59þ Relaxtion þ
SR
Indiv 6 Plac
Lovato 2014 [47] Comm WASO > 30 m,  3 n/w, >
6 mo þ daytime imp
3 m 118 Tx: 72/86 (84%); C: 27/32
(84%)
Exluded Older CBT-I Group 4 WL






40e65 CBT-I Phone n/a Menopause
education
Morin 2005 [37] Comm Diagnostic criteria for
insomnia: (1) complaint
of poor sleep quality or
dissatisfaction regarding
sleep; (2) symptoms of
initial, maintenance, or
late insomnia at least 3




sleep difficulties; and (4)
presence of the sleep
difficulties for at least 1
mo.
6 m 192 Tx: 81/96 (84%); C: 86/96
(90%)
Allowed 18þ CBT-I Self-help n/a No txt
Rybarczyk 2002 [34] Care SOL  45 m or
WASO  60 m or
TST  5 h,  3 n/w
3 m 24 Tx: 10/16 (63%); Tx2: 13/
18 (72%); C: 12/17 (71%)
Illnesses 55þ CBT-I Group/
Self-help
8 n/a WL
Savard 2016 [48] Care ISI  8 or  2 nights of
sleep medication in last 2
wk
3m þ 6m þ
12m
242 Tx1: 61/81 (75%); Tx2:
49/80 (61%); C: 49/81
(60%)



























































































































































































































































































































































































































































































































































































































































































































































T. van der Zweerde et al. / Sleep Medicine Reviews 48 (2019) 101208 5(e.g., anyone over 18, or older adults only), 6) the treatment format
(individual, group or self-help), 7) number of sessions, 8) the con-
trol group (e.g., waitlist, no treatment) and 9) type of intervention.
We categorized studies in four categories of interventions: 1) full
CBT-I, including an educational component as well as a behavioral
and cognitive one, 2) behavioral therapy, including both stimulus
control and sleep restriction, 3) relaxation therapy only, and 4)
“other”, including e.g., stimulus control only or paradoxical inten-
tion only. Two independent assessors coded the studies (TvdZ and
LB). Differences were discussed amongst the review team until
consensus was reached (TvdZ, LB, JL and AvS).
Quality assessment
Using the criteria suggested in the Cochrane handbook [17], we
assessed the validity of the studies: 1) adequate sequence genera-
tion, 2) concealment of allocation, 3) adequate handling of
incomplete outcome data, and 4) selective reporting of data.We did
not assess the blinding of patients or therapists since this is not
possible in psychotherapy research nor did we assess blinding of
outcome assessors since all reported outcomes are based on self-
report. Two reviewers conducted the quality assessment indepen-
dently of each other (TvdZ and LB) and then crosschecked their
findings.
Meta-analysis
We focused on the effects on insomnia severity primarily
(measured through questionnaires), and secondarily on sleep onset
latency (SOL) and sleep efficiency (SE) measured through sleep
diaries because these are among the most important sleep out-
comes and yielded the largest number of comparisons. We defined
an effect as “long-term” if it was measured at least 12 wk after the
end of treatment. We created three subgroups, grouped in 1) three
months (between 12- and 17.5-wk post-treatment), 2) six months
(between 18 and 35 wk) and 3) 12 mo (more than 35 wk) for
pragmatic reasons. There were no studies reporting outcomes after
one year. Where the exact timing of the follow-up assessment was
unclear from the articles (i.e., post-baseline or post-treatment), we
contacted the authors. Whenwe did not receive a reply (n ¼ 1), we
assumed the reported follow-up period was post-treatment
(however, this assumption did not influence the group assign-
ment of this study).
We computed Hedges' g to determine between group effect
sizes. Hedges' g is a measure of standardized mean differences
(similar to Cohen's d), after adjusting for small sample sizes [18,19].
This effect size (based on the differences between conditions at the
different time points) can be interpreted as the difference between
the mean scores of the two groups expressed in the number of
weighted pooled standard deviations. Effect sizes (ES) are
commonly interpreted as either large (>0.56), moderate
(0.33e0.55) or small (0e0.32) [20]. The available statistics (means,
standard deviations, standard errors, 95% confidence intervals, and
interquartile ranges) from the included studies were used to
compute the ESs using the metafor package in R [21].
We checked for outliers by visually inspecting forest plots for all
analyses. We defined outliers as studies in which we found a 95%
confidence interval around the ES that did not show overlap with
the 95% confidence interval of the pooled effect size. One study was
identified to be an outlier [22] on all variables it included (SOL,
WASO, SE, TST and ISI at 3 mo and 6 mo). Based on author
consensus we removed this study from the analysis because we
judged it to be a significant and pronounced outlier.
In the 12 mo follow-up, one study had to be excluded from the
analysis because means were not provided and could not be
T. van der Zweerde et al. / Sleep Medicine Reviews 48 (2019) 1012086calculated from what was reported (WASO and TST) [23]. For SOL,
two studies did not report a measure of dispersion [23,24], but
effect sizes were calculated using other available statistics.
Expecting the studies to show significant heterogeneity, we
used the random effects model in the metafor package [21] to es-
timate the weighted pooled effect sizes for the different outcome
measures. Heterogeneity was inspected under the fixed effects
model using I2, describing the variance between studies as a pro-
portion of the total variance. A value of 0% means there is no
observed heterogeneity, with larger percentages indicating more
heterogeneity [25]. The 95% confidence intervals around I2 were
calculated.
To address treatment heterogeneity in the included studies we
performed sensitivity analyses, exploring differences in effects of
full CBT-I compared to effects of partial CBT-I or monotherapy.
To assess potential publication bias, we visually inspected the
funnel plot and conducted Egger's test for all variables, at the three
different time points [26]. The Duval and Tweedie [27] trim and fill
procedurewas used to adjust the effect size for publication bias and
to provide an indication of the number of studies that might have
been missing from the analysis.
Results are reported in accordance with the PRISMA statement
and the PRISMA checklist can be found in the supplement [28].
Results in the expected and desired direction are reported as pos-
itive results, results in the undesired direction (i.e., worsening of
symptoms) are reported as negative results.
Results
Selection of included studies
We selected studies using two strategies. First, we included ar-
ticles identified in the previous meta-analysis [9], which had
controlled 12 wk or more follow-up data. A total of 25 studies were
found using this method [23,24,29e50]. Secondly, we performed a
new literature search for the period since the previous meta-
analysis [9]. We screened 420 titles and abstracts and excluded
324 as not relevant and/or not meeting criteria based on their titles
and abstracts. In total, we then assessed 96 full texts. Of these, we
excluded 66 articles because 1) duplicates between the first and
second search strategy (n ¼ 5), 2) not a controlled RCT (n ¼ 24), 3)
no CBTcomponent (n¼ 3), 4) not focused on insomnia (n¼ 9), 5) no
sleep diary (n¼ 14), 6) no follow-up (n¼ 3), 7) no datawe could use
for calculations of the effect sizes (n ¼ 5) or 8) not a results paper
(n ¼ 3). The remaining 30 papers were included in this meta-
analysis: the 25 already included in our previous meta-analysis
and five new papers reporting follow-up results of an RCT on (a
component of) CBT-I compared to an inactive control group
[51e55]. A flowchart of the inclusion and exclusion process is in
Fig. 1.
Two studies compared different active interventions in com-
parison to a control condition. Therefore, the meta-analysis
included 32 comparisons in total. Some studies (n ¼ 9) reported
multiple follow-up measurements and not all studies reported the
same sleep variables. The numbers of comparisons vary in the
different analyses and are listed in the tables.
Study characteristics
Eighteen studies reported three months follow-up data
[22,29e32,34,38,42e45,47,48,50,51,53e55], fourteen studies re-
ported data for six months follow-up [22,36e41,46,48e52,55] and
eight studies reported 12 mo follow-up data [23,24,
33,35,46,48,49,52]. The oldest study in our sample was published
in 1976 [24]. The large majority was published after 2000 (n ¼ 28;93%). Fourteen studies (47%) investigated community samples, 15
studies (50%) recruited patients from care settings and one study
recruited within a university (3%). Around 50% of the studies
(n ¼ 16) excluded patients showing (specific) comorbidities. The
remaining 14 studies did not, or did not report it. Out of the 30
studies included in the qualitative assessments, twenty studies
(67%) offered full CBT-I, the others (n ¼ 10; 33%) offered one or
more components of CBT-I but not the full package. Treatment was
offered in group format in 13 studies, in individual format in 13
studies and in self-help format in six studies (total n¼ 32 treatment
groups across studies). Treatment groups were compared to wait-
list (n ¼ 8), no treatment (n ¼ 7), care-as-usual (n ¼ 2), placebo
(n ¼ 6) or minimal intervention (n ¼ 8) control groups (total n ¼ 31
control groups across studies). See Table 1 for details.
Quality assessments
Sixteen out of the 30 studies included in the qualitative as-
sessments (53%) generated randomization sequences adequately,
whereas 14 (47%) did not, or did not report on it. A total of 13
studies (43%) reported adequate concealing of the random alloca-
tion, for the other 17 studies (57%) this was not reported. Twenty
studies (67%) reported handling missing data by performing intent-
to-treat analysis, six studies (20%) did not conduct intent-to-treat
analysis and four (13%) did not report how they handled missing
data. Eight studies (27%) seemed to be selective in reporting of data
based on comparisons of study protocols to results reported.
Three to 12 mo effects on insomnia severity, sleep efficiency and
sleep onset latency
Three months after CBT-I finished the effect compared to the
non-treated controls on ISI was statistically significant and large
(g¼ 0.64; Nc¼ 13). The effect remained present after threemonths,
with a moderate between group effect size at six months (g ¼ 0.40;
Nc ¼ 8) and a small between group effect size at 12 mo (g ¼ 0.25;
Nc ¼ 4).
Three months after CBT-I was finished the effect on sleep effi-
ciency was moderate (g ¼ 0.51; Nc ¼ 21) and remained relatively
stable over time (six months: g ¼ 0.32; Nc ¼ 16); 12 mo g ¼ 0.35;
Nc ¼ 8). The effect size of CBT-I on SOL declined from moderate at
three months to small at six months but returned to moderate at 12
mo (g ¼ 0.38, 0.29 and 0.40 respectively with Nc ¼ 21, 16, and 10).
Forest plots for ISI, SE and SOL can be found in Figs. S1eS3.
Three to 12 mo effects on secondary outcomes
For the secondary variables, treated groups outperformed the
control groups at three months on most variables (PSQI: g ¼ 0.80;
Nc ¼ 6; WASO: g ¼ 0.42; Nc ¼ 20; SQ g ¼ 0.49; Nc ¼ 5). Effects on
TST (g ¼ 0.06; Nc ¼ 21) and NWAK (g ¼ 0.08; Nc ¼ 4) were not
significant (see Table 2). At six months, effects were present, but
most had become slightly smaller (WASO: g ¼ 0.27; Nc ¼ 13; PSQI:
g¼ 0.48; Nc¼ 3). Effects on SQ (g¼ 0.09; Nc¼ 2) and TST (g¼ 0.05;
Nc ¼ 15) were non-significant. NWAK data were not available at six
months. At 12 mo, results are less reliable due to the small number
of studies included in the analysis (WASO: g¼ 0.26; Nc¼ 8; NWAK:
g ¼ 0.52; Nc ¼ 2). Effects on PSQI, SQ and TST were not significant
(PSQI: g¼ 0.22; Nc¼ 2; SQ: g¼ 0.24; Nc¼ 3; TST: g¼ 0.03; Nc¼ 7).
Differences between post-test effects of studies with long-term
effects vs all studies
We calculated the post-test effect sizes of the 29 studies
(excluding one outlier) in the current meta-analysis (ISI, SE, SOL).
T. van der Zweerde et al. / Sleep Medicine Reviews 48 (2019) 101208 7We then divided the studies based on follow-up length and
compared the post-test effects of studies with 3 mo follow-up, 6
mo follow-up and 12 mo follow-up to the overall post-test effect
sizes (results are in Supplementary Table S1).
Sensitivity analysis
We made a comparison between the sample with all studies
included to the sample with only the studies with full CBT-I. Due to
variety in follow-up length and reported variables there were
different samples only for ISI (3m), SOL (3/6/12m), and SE (3/12m;
see Supplemental Table S2 for Nc's and effect sizes). The differences
in g ranged from 0.01 to 0.05.We also compared the samplewith all
studies included with the sample excluding monotherapies. There
were different samples only for SE (Nc ¼ 8 versus 6) and SOL
(Nc ¼ 10 vs 8), both at 12 m. The difference in g was 0.03 for both
(see Supplemental Table S2).
Publication bias
We found indications for publication bias in only one of the
analyses performed: the three-month follow-up effects on totalFig. 1. PRISMA 2009sleep time. Egger's test for funnel plot asymmetry was significant
(t ¼ 2.38, df ¼ 19, p ¼ .028). We performed a trim and fill analysis
and found the estimated number of studies missing on the left side
of the funnel plot to be n¼ 1. The effect size adjusted for publication
bias for three-month TSTwas 0.039 (p¼ .601), slightly smaller than
the 0.061 (p ¼ .391) unadjusted effect size, and remained statisti-
cally non-significant.
Discussion
We performed a meta-analysis on 29 RCTs (removing one study
which was an outlier) to investigate the long-term effects of
cognitive and/or behavioral treatments for insomnia. We studied
three, six and 12-mo follow-up data in separate analyses. Three
months after treatment, the severity of insomnia complaints (pri-
mary outcome) was considerably better for patients treated with
CBT-I than for patients without an active treatment (ISI: g ¼ 0.64).
Effects were of moderate size at six months (ISI: g ¼ 0.40). At 12
mo the treated group still outperformed the control group, albeit
showing a smaller effect size (ISI: g ¼ 0.25). The sleep diary vari-
ables (sleep efficiency and sleep onset latency; secondary out-










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































T. van der Zweerde et al. / Sleep Medicine Reviews 48 (2019) 1012088for three months outcomes (SE: g ¼ 0.51; SOL: g¼ 0.38). In general,
there seems to be a steady decline over time, indicating that the
long-term effects of CBT-I are smaller than effects observed in the
short term [7e9].We identify three possible reasons for this decline
in effects over time.
Firstly, it could be an artefact specific to this meta-analysis.
The analyses at the different time points include different
studies and this could lead to biased effect size estimates. For
instance, the decline in effect may be related to our decision to
include only a subset of studies, those with controlled follow-up
data. In our view this is a major strength of our analysis since it
allowed us to infer whether treatment effects at long-term are
actually due to the treatment and not caused by the passage of
time. However, the lower effect sizes could reflect this meta-
analysis not being a representative sample of studies on CBT-I
post-test effects.
To address this, we compared the post-test effects of studies
with 3, 6- and 12-mo follow-up to overall post-test effect sizes (See
Supplemental Table S1). When compared to the post-test effects in
our previous meta-analysis (ISI, g ¼ 0.98) [9], the present sample
showed relatively similar effect sizes and overlapping confidence
intervals at post-test: 3 mo, g ¼ 0.91, 6 mo, g ¼ 0.62; 12 mo,
g ¼ 0.79; all studies in the current meta-analysis, g ¼ 0.83. For the
sleep diary variables, the differences were also relatively small:
sleep efficiency effect size was g ¼ 0.71 in the previous meta-
analysis [9]. Now effect sizes ranged between 0.53 and 0.74 (all
with overlapping confidence intervals). The same pattern was
observed for SOL with and effect size of g ¼ 0.57 in [9], effect sizes
now ranging between 0.45 and 0.58 (with overlapping confidence
intervals). Overall, the post-test effect sizes of the studies including
controlled follow-up studies seem to be in a somewhat lower
range. However, an artefact effect in our sample is not likely to be
the sole explanation.
A second possible reason is that the patients in the control
conditions start sleeping better over time, either because they have
sought treatment elsewhere or merely as a result of time passing.
When looking at the data from the individual studies included in
this meta-analysis, we do observe control participants reporting a
small decrease in insomnia symptoms. We do not know whether
control patients have undergone treatment. As the time of follow-
up increases, so does the window of opportunity to seek treatment
elsewhere. Earlier research on the natural course of insomnia re-
ports that insomnia is often persistent when untreated [56], sug-
gesting the symptom decrease in control participants is unlikely to
have happened spontaneously. A three-year follow-up study by
Blom and colleagues showed that during the follow-up phase,
control group participants were indeed likely to use sleep medi-
cation and seek additional insomnia treatment elsewhere [57]. Our
results may therefore be on the conservative side: if control par-
ticipants have sought effective help elsewhere, this may have led to
a smaller difference between the treatment conditions and the
controls.
A third possible reason is an increase in the intervention par-
ticipants' insomnia symptoms over time. Again, when looking at
the data for the individual studies included in this meta-analysis,
we see that on average intervention participants report a slight
return of symptoms over time. This would mean the effects of the
intervention in the long run are not as pronounced as is often
thought. This explanation seems plausible: the interventions are
relatively short, and focus on behavioral changes (e.g., lifestyle,
bedtimes, sleep hygiene). These behavior changes can be hard to
stick to, as we know from extensive research in other areas of
preventive care where lifestyle changes are necessary (e.g.,
increasing physical activity, smoking cessation, reducing alcohol
consumption [58].)
Practice points
- Cognitive behavioral therapy for insomnia is effective on
insomnia severity, sleep efficiency and sleep onset latency
at three, six- and 12-mo follow-up.
- Long-term effects provide support for international
guidelines recommending cognitive behavioral therapy
as the first treatment option for insomnia.
Research agenda
Future studies on cognitive behavioral treatment for
insomnia should aim to:
- Include long-term controlled follow-ups
- Provide information on daytime functioning as a conse-
quence of insomnia and changes in functioning after
treatment
- Be uniform in reporting on randomized controlled trials
and adequately monitor control participants during the
follow-up phase.
T. van der Zweerde et al. / Sleep Medicine Reviews 48 (2019) 101208 9Our results, therefore, may be explained by an interplay be-
tween these three explanations. To answer this question more
definitively, we need more randomized controlled trials that
include a long and controlled follow-up with multiple measure-
ments (e.g., 3 mo and 12 mo) reporting on what happens in the
follow-up phase as well. It would also be good to adopt a more
uniform research approach in reporting on (long-term) treatment
trials. For this meta-analysis, included studies showed substantial
heterogeneity. Furthermore, not all variables investigated were
reported in all included studies, limiting the number of compari-
sons. Pragmatic choices had to be made in choosing outcome var-
iables that present a balanced picture, but SE in particularmight not
be an ideal outcome to report [59]. Given the small number of
studies reporting 12-mo follow-up data (n ¼ 8), results at 12
mo should be interpreted with caution. To enhance uniformity, we
advise CBT-I researchers to include the Carney consensus diary
variables [60] and the ISI [61] in future research. This would in-
crease the opportunities for meaningful pooling of evidence and
also allowmeaningful subgroup analyses providing insight into the
variables influencing magnitude of effect size.
The heterogeneity of included studies is a potential limitation of
this meta-analysis. Studies differ in terms of comorbid populations,
delivery mode and treatment content. We decided to include these
studies for several reasons: 1) Current diagnostic practice no longer
makes a distinction between primary and secondary/comorbid
insomnia. 2) previous research shows delivery mode is not an
important factor determining effects [62,63]. 3) the previous meta-
analysis by van Straten and colleagues (2018) showed full CBT-I
effects did not differ from those of partial CBT-I [9]. Sensitivity
analysis on the current dataset supported our choice
(Supplemental Table S2).
Importantly, although the effects decline somewhat over time,
we did find sustained long-term CBT-I effects. These established
long-term effects strengthen the claim that CBT-I outperforms
pharmacotherapy in the long run and is the preferred treatment for
insomnia (e.g., [13]). The sustained and (tentatively) clinically
relevant effects (ES > 0.25 for depression treatment according to
Cuijpers and colleagues [64]) are of particular interest. It must be
noted however that relatively few meta-analyses on other psy-
chological disorders have established long-term controlled treat-
ment effects [65e67]. Meta-analyses are often limited to short-
term effects, due to difficulties interpreting varied follow-up in-
tervals and potential for other treatments or life events during the
longer follow-up phase [67]. The few meta-analyses that have
investigated long-term effects have generally reported similar
findings: sustained (but somewhat declined) long-term treatment
effects for CBT for depression [68,69], anxiety [70] and PTSD [71].
To enhance long-term effects, perhaps we need to put more
emphasis on relapse prevention within CBT-I. Currently, relapse
prevention is a component of most interventions at the end of
treatment, making patients aware of the potential of relapse. They
are advised to return to the exercises in the intervention when this
happens. This could be improved, for example, by adding a booster
session after six months or asking patients to continue keeping a
sleep diary for a longer period of time.
Taken together, the results of the present meta-analysis show
favorable effects of CBT-I at follow-up, still present (albeit smaller)
at 12 mo after treatment. Establishing this long-term effect is of
major importance: it provides a strong argument for the clinical
recommendation of offering CBT-I.
Ultimately, the main goal of CBT-I is to improve daytime func-
tioning, improving quality of life and reducing societal costs due to
absenteeism and work productivity losses. Research on long-termeffects of CBT-I on these measures is currently scarce, although
daytime impairment is the main reason patients seek treatment
[2,72]. This meta-analysis indicates that CBT-I does show the often-
claimed long-term effectiveness, but it is not without its limita-
tions. In further insomnia research, we need to aim for more uni-
formity and more controlled studies with a longer follow-up
(preferably one year). This would enable confidently stating that
CBT-I has the often-proclaimed long term effects, improves both
insomnia severity and daytime functioning and should be the first
treatment of choice, in line with recent recommendations for the
treatment of insomnia symptoms [12,13].
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